2023 World Conference on Lung Cancer (Posters)-EP17.03. The Economic Evaluation of The protein-Based Lung Cancer Biomarker Panel (LCBP):Evidencebased Onamulticenter Clinicaltrialin China

EP17.03. The Economic Evaluation of The protein-Based Lung Cancer Biomarker Panel (LCBP):Evidencebased Onamulticenter Clinicaltrialin China - PDF(Abstract)

Back to course

Pdf Summary

This document discusses the economic evaluation of a protein-based lung cancer biomarker panel (LCBP) in China. The early diagnosis of lung cancer is crucial for effective disease management, as many patients are asymptomatic when seeking treatment. The LCBP is a panel of serum biomarkers that can aid in the early detection of lung cancer in high-risk populations. A multicenter clinical trial was conducted to assess the performance of the LCBP using real-world clinical data. The results showed that the LCBP had significant discrimination ability in identifying lung cancer risk factors, supporting early diagnosis and appropriate clinical management.<br /><br />To further evaluate the clinical cost-effectiveness of the LCBP, an economic evaluation was conducted. The cost data were obtained from a real-world study, and a cost utility analysis methodology was used to estimate the incremental cost-effectiveness ratio (ICER). The results showed that the LCBP was cost-effective, with estimated incremental costs of 5032.48 yuan/year for the lung cancer risk model and 59589.61 yuan/year for the lung nodules model. The early detection and effective management of lung cancer patients using the LCBP can help avoid downstream costs from complications and improve patients' overall survival quality.<br /><br />The study aims to assess the economic impact of the protein-based LCBP based on clinical evidence. By demonstrating its cost-effectiveness, the LCBP provides a valuable tool for early diagnosis and management of lung cancer. The findings of this study contribute to the understanding of the economic implications of implementing the LCBP in clinical practice.<br /><br />Overall, this research highlights the importance of early diagnosis in lung cancer management and provides evidence for the economic benefits of using the protein-based LCBP in China.

Asset Subtitle

Dawei Yang

Meta Tag

Speaker Dawei Yang

Topic Global Health, Health Services & Health Economics: Health Economics

Keywords

protein-based lung cancer biomarker panel

LCBP

economic evaluation

China

early diagnosis

lung cancer

serum biomarkers

high-risk populations

clinical trial

cost-effectiveness